Patents by Inventor Chris J. Vlahos

Chris J. Vlahos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
    Patent number: 5726167
    Abstract: Viridin, viridiol, demethoxyviridin, demethoxyviridiol, virone, and wortmannolone, and analogs thereof, are inhibitors of phosphatidylinositol 3-kinase. The compounds are particularly useful for inhibiting phosphatidylinositol 3-kinase in vertebrates and for treating phosphatidylinositol 3-kinase-dependent conditions, especially neoplasms, restenosis and atherosclerosis, and bone disorders in vertebrates.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: March 10, 1998
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey A. Dodge, Masahiko Sato, Chris J. Vlahos
  • Inhibition of phosphatidylinositol 3-kinase with 17 .beta.-hydroxywortmannin and analogs thereof
    Patent number: 5504103
    Abstract: 17.beta.-hydroxywortmannin and certain of its analogs are inhibitors of phosphatidylinositol 3-kinase. The compounds are particularly useful for inhibiting phosphatidylinositol 3-kinase in mammals and for treating phosphatidylinositol 3-kinase-dependent conditions, especially neoplasms, in mammals.
    Type: Grant
    Filed: August 25, 1993
    Date of Patent: April 2, 1996
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jeffrey A. Dodge, Chris J. Vlahos
  • Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
    Patent number: 5378725
    Abstract: Wortmannin and certain of its analogs are inhibitors of phosphatidylinositol 3-kinase. The compounds are particularly useful for inhibiting phosphatidylinositol 3-kinase in mammals and for treating phosphatidylinositol 3-kinase-dependent conditions, especially neoplasms, in mammals.
    Type: Grant
    Filed: July 19, 1993
    Date of Patent: January 3, 1995
    Assignees: The Arizona Board of Regents, Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Chris J. Vlahos, Garth Powis